Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Truqap in Advanced Solid Tumors with AKT Mutations
NCT03310541Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2017
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capivasertib in solid tumor (advanced stage), breast cancer and prostate cancer (PCa) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 1 year. Started Oct 2017; status: completed.
02
Drugs
capivasertib
03
Conditions
solid tumor (advanced stage)breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03310541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310541.